EVADRY® in the Treatment of Xerostomia in Sjögren's Syndrome

NANot yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Sjogren's Syndrome
Interventions
DIETARY_SUPPLEMENT

EVADRY

"The EVADRY oral spray and the placebo are produced by Wellnet laboratory.~• EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg)."

OTHER

Placebo

"The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY.~Both products are administered at a rate of 5 intra-oral sprays per day."

All Listed Sponsors
lead

University Tunis El Manar

OTHER

NCT06313905 - EVADRY® in the Treatment of Xerostomia in Sjögren's Syndrome | Biotech Hunter | Biotech Hunter